AZTR

The company's research is centered on precision dermatology, primarily using engineered strains of a common skin bacterium, Staphylococcus epidermidis. These genetically modified live biotherapeutic products are designed to be applied topically to treat specific rare and severe diseases. The company's lead candidate, ATR-04, is in a Phase 1/2 clinical trial evaluating its potential to treat a severe, acne-like rash experienced by cancer patients on certain targeted therapies. Another program, ATR-12, is in a Phase 1b/2a trial for Netherton syndrome, a genetic skin disorder. A third candidate, ATR-01, is in preclinical development for a condition called ichthyosis vulgaris.

Azitra aims to address diseases with significant unmet medical need through its platform. The company has also established a collaboration with Bayer for the discovery of new bacterial strains. Founded in 2014, Azitra operates as a clinical-stage biopharmaceutical company with a pipeline of programs targeting specific dermatological indications where current treatment options are limited.